Review of COVID-19 Antibody Therapies
In the global health emergency caused by coronavirus disease 2019 (COVID-19), efficient and specific therapies are urgently needed. Compared with traditional small-molecular drugs, antibody therapies are relatively easy to develop; they are as specific as vaccines in targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); and they have thus attracted much attention in the past few months. This article reviews seven existing antibodies for neutralizing SARS-CoV-2 with 3D structures deposited in the Protein Data Bank (PDB). Five 3D antibody structures associated with the SARS-CoV spike (S) protein are also evaluated for their potential in neutralizing SARS-CoV-2. The interactions of these antibodies with the S protein receptor-binding domain (RBD) are compared with those between angiotensin-converting enzyme 2 and RBD complexes. Due to the orders of magnitude in the discrepancies of experimental binding affinities, we introduce topological data analysis, a variety of network models, and deep learning to analyze the binding strength and therapeutic potential of the 14 antibody-antigen complexes. The current COVID-19 antibody clinical trials, which are not limited to the S protein target, are also reviewed.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Annual review of biophysics - 50(2021) vom: 06. Mai, Seite 1-30 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Jiahui [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.05.2021 Date Revised 11.11.2023 published: Print-Electronic UpdateOf: ArXiv. 2020 Jun 18;:. - PMID 32601601 Citation Status MEDLINE |
|---|
| doi: |
10.1146/annurev-biophys-062920-063711 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316340510 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316340510 | ||
| 003 | DE-627 | ||
| 005 | 20231225160854.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1146/annurev-biophys-062920-063711 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316340510 | ||
| 035 | |a (NLM)33064571 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Jiahui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Review of COVID-19 Antibody Therapies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2021 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: ArXiv. 2020 Jun 18;:. - PMID 32601601 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In the global health emergency caused by coronavirus disease 2019 (COVID-19), efficient and specific therapies are urgently needed. Compared with traditional small-molecular drugs, antibody therapies are relatively easy to develop; they are as specific as vaccines in targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); and they have thus attracted much attention in the past few months. This article reviews seven existing antibodies for neutralizing SARS-CoV-2 with 3D structures deposited in the Protein Data Bank (PDB). Five 3D antibody structures associated with the SARS-CoV spike (S) protein are also evaluated for their potential in neutralizing SARS-CoV-2. The interactions of these antibodies with the S protein receptor-binding domain (RBD) are compared with those between angiotensin-converting enzyme 2 and RBD complexes. Due to the orders of magnitude in the discrepancies of experimental binding affinities, we introduce topological data analysis, a variety of network models, and deep learning to analyze the binding strength and therapeutic potential of the 14 antibody-antigen complexes. The current COVID-19 antibody clinical trials, which are not limited to the S protein target, are also reviewed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody therapy | |
| 650 | 4 | |a binding affinity | |
| 650 | 4 | |a deep learning | |
| 650 | 4 | |a network analysis | |
| 650 | 4 | |a persistent homology | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Gao, Kaifu |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Nguyen, Duc Duy |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Guo-Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annual review of biophysics |d 2008 |g 50(2021) vom: 06. Mai, Seite 1-30 |w (DE-627)NLM180395009 |x 1936-1238 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2021 |g day:06 |g month:05 |g pages:1-30 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1146/annurev-biophys-062920-063711 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2021 |b 06 |c 05 |h 1-30 | ||